Search
01/01/2022
Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA Study)
Hernández-Cruz B., Rosas J., Díaz-Torné C., Belzunegui J., García-Vicuña R., Inciarte-Mundo J., Pons A., Millán A.M., Jeria-Navarro S., Valero J.A., García-Castañeda N., Valero C., Llorente I., Calvo A., Díaz-Cerezo S., Núñez M.. Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA Study). Rheumatology and Therapy. 2022; 9(2)DOI:10.1007/s40744-021-00423-8. PMID:35041155. IF:3.800(Q3/6D).
01/01/2022
Long-term exposure to PM10 above WHO guidelines exacerbates COVID-19 severity and mortality
Marquès M., Correig E., Ibarretxe D., Anoro E., Antonio Arroyo J., Jericó C., Borrallo R.M., Miret M., Näf S., Pardo A., Perea V., Pérez-Bernalte R., Ramírez-Montesinos R., Royuela M., Soler C., Urquizu-Padilla M., Zamora A., Pedro-Botet J., Masana L., Domingo J.L.. Long-term exposure to PM10 above WHO guidelines exacerbates COVID-19 severity and mortality. ENVIRONMENT INTERNATIONAL. 2022; 158DOI:10.1016/j.envint.2021.106930. PMID:34678637. IF:11.800(Q1/1D).
01/08/2025
Platelet bound B cells and their role in SSc: Implications for disease subtypes and clinical outcomes
Osuna-Gómez, R, Castellví, I, Mulet, M, Tandaipan, JL, Zamora, C, Codes-Mendez, H, Ortiz, MA, Diaz-Torné, C, Cantó, E, Magallares, B, Guinart-Cuadra, A, Moya, P, Corominas, H, Vidal, S. Platelet bound B cells and their role in SSc: Implications for disease subtypes and clinical outcomes. Translational Research. 2025; 282DOI:10.1016/j.trsl.2025.07.001. PMID:40645372. IF:5.900(Q1/1D).
01/08/2025
Usefulness of ultrasound in the assessment of the efficacy of apremilast in psoriatic arthritis: Articular, enthesitic and nail index
de Agustin, JJ, Añez, GA, Reina, D, Heredia, S, Ramirez, J, Cuervo, AM, Rodriguez, J, Moragues, C, Moya, P, Alonso, AML, Moreno, M, Arevalo, M, Pujol, M, Salvador, G, Busquets, N, Ponce, A, Pastor, MP. Usefulness of ultrasound in the assessment of the efficacy of apremilast in psoriatic arthritis: Articular, enthesitic and nail index. Reumatologia Clinica. 2025; 21(7)DOI:10.1016/j.reuma.2025.501921. PMID:. IF:(Q/D).
01/06/2025
Core domain set for chronic and/or recurrent manifestations of calcium pyrophosphate deposition disease: OMERACT delphi survey to establish consensus
Zhang, YL, Tedeschi, SK, Abhishek, A, Hensey, O, Grossberg, D, Cai, K, Shea, B, Singh, JA, Christensen, R, Serban, T, Cipolletta, E, Parperis, K, Diaz-Torne, C, Mccarthy, GM, Becce, F, Gheita, TA, Sirotti, S, Christiansen, SN, Coronel, L, Stamp, LK, Abdel-Fattah, YH, Pascart, T, Filippou, G, Hong, LE, Fitzgerald, J, Dalbeth, N. Core domain set for chronic and/or recurrent manifestations of calcium pyrophosphate deposition disease: OMERACT delphi survey to establish consensus. SEMINARS IN ARTHRITIS AND RHEUMATISM. 2025; 72DOI:10.1016/j.semarthrit.2025.152669. PMID:40086154. IF:4.400(Q1/1D).
01/06/2025
FACTORS ASSOCIATED WITH ACHIEVING REMISSION OR LOW DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING JANUS KINASE INHIBITOR TREATMENT
Martinez-Molina, C, Park, HS, Díaz-Torné, C, Vidal, S, Corominas, H. FACTORS ASSOCIATED WITH ACHIEVING REMISSION OR LOW DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING JANUS KINASE INHIBITOR TREATMENT. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B3700. PMID:. IF:20.600(Q1/1D).
01/06/2025
CLINICAL AND ULTRASOUND FEATURES OF A COHORT OF PSO PATIENTS WITHOUT MUSCULOSKELETAL SYMPTOMS: A PROSPECTIVE AND MULTICENTER STUDY
Azuaga, AB, Cuervo, A, Reina, D, Estrada, P, Soria, LM, Aparicio, M, Moreno, M, Arevalo, M, Laiz, A, Moya, P, Alascio, L, Riera, J, Scher, JU, Crespillo, JDDC, Ramirez, J. CLINICAL AND ULTRASOUND FEATURES OF A COHORT OF PSO PATIENTS WITHOUT MUSCULOSKELETAL SYMPTOMS: A PROSPECTIVE AND MULTICENTER STUDY. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B1990. PMID:. IF:20.600(Q1/1D).
01/06/2025
EVALUATION OF THE NEW CRITERIA FOR PROGRESSIVE PULMONARY FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS
Retuerto-Guerrero, M, Morales, CM, Santos, CS, Herránz, LS, Juan, J, Castellví, I, Alvarez, ED. EVALUATION OF THE NEW CRITERIA FOR PROGRESSIVE PULMONARY FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B1643. PMID:. IF:20.600(Q1/1D).
01/06/2025
COMPARATIVE ANALYSIS OF PROGRESSIVE PULMONARY FIBROSIS CRITERIA IN SYSTEMIC SCLEROSIS PATIENTS
Retuerto-Guerrero, M, Morales, CM, Santos, CS, Herránz, LS, Juan, J, Castellvi, I, Alvarez, ED. COMPARATIVE ANALYSIS OF PROGRESSIVE PULMONARY FIBROSIS CRITERIA IN SYSTEMIC SCLEROSIS PATIENTS. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B1597. PMID:. IF:20.600(Q1/1D).
01/06/2025
DISTINCTIVE CLINICAL TRAITS OF ANTICENTROMERE ANTIBODY-POSITIVE SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A MULTICENTER RETROSPECTIVE STUDY
Valera-Ribera, C, Alegre-Sancho, JJ, Castellvi, I, Ibanez, M, Garcia, FJN. DISTINCTIVE CLINICAL TRAITS OF ANTICENTROMERE ANTIBODY-POSITIVE SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: A MULTICENTER RETROSPECTIVE STUDY. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B3437. PMID:. IF:20.600(Q1/1D).
01/06/2025
UNDERSTANDING THE IMPACT OF EMA/PRAC SAFETY RECOMMENDATIONS ON THE REAL-WORLD USE OF JAK INHIBITORS IN RA
Paños, HB, Saborit, MC, Lasanta, MAL, Lizarzaburu, MS, Ruiz-Esquide, V, Vilaseca, DR, Nack, A, Perez-Garcia, C, Bernardez, J, Guillen, AG, Aguilar, JR, Cuervo, A, Roc, MV, Gomez, CG, Mínguez, S, Novell, RM, Estrada, P, Martinez-Morillo, M, Grau, CP, Busquets-Perez, N, Park, HS, Gómez-Puerta, JA, Pérez, SH, Palau, NM, Sanmarti, R, Mateo, L, Diaz-Torne, C, Corominas, H, Alarcon, GS. UNDERSTANDING THE IMPACT OF EMA/PRAC SAFETY RECOMMENDATIONS ON THE REAL-WORLD USE OF JAK INHIBITORS IN RA. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B3117. PMID:. IF:20.600(Q1/1D).
01/06/2025
PROGNOSTIC VALUE OF HYPERURICEMIA IN DEVELOPING CARDIOVASCULAR EVENTS IN PATIENTS WITH CHRONIC INFLAMMATORY ARTHRITIS: A 10-YEAR PROSPECTIVE STUDY
Avilés, A, Plaza, Z, Sánchez-Alonso, F, Castañeda, S, Fernández-Gutiérrez, B, Diaz-Torne, C, Pilar, FU, González, OM, Gallego, JMS, Giner, E, Cid, AR, Gómez, AP, Nievas, GS, García, J, Juanatey, CG, Llorca, J, González-Gay, MA, Andrés, M. PROGNOSTIC VALUE OF HYPERURICEMIA IN DEVELOPING CARDIOVASCULAR EVENTS IN PATIENTS WITH CHRONIC INFLAMMATORY ARTHRITIS: A 10-YEAR PROSPECTIVE STUDY. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.A1239. PMID:. IF:20.600(Q1/1D).
01/06/2025
EFFECTIVENESS AND SAFETY OF JANUS KINASE INHIBITORS IN GIANT CELL ARTERITIS. REAL-WORLD CLINICAL PRACTICE STUDY AND LITERATURE REVIEW
López-Gutiérrez, F, Loricera, J, Tofade, T, Prieto-Peña, D, Romero-Yuste, S, De Miguel, E, Riveros-Frutos, A, Nuñez, DF, Ferraz-Amaro, I, Castañeda, S, Labrador-Sánchez, E, Maiz, O, Garcia, FJN, Galindez-Agirregoikoa, E, González, I, Urruticoechea-Arana, A, Calvo, AR, Moya, P, Unizony, S, Blanco, R. EFFECTIVENESS AND SAFETY OF JANUS KINASE INHIBITORS IN GIANT CELL ARTERITIS. REAL-WORLD CLINICAL PRACTICE STUDY AND LITERATURE REVIEW. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B2775. PMID:. IF:20.600(Q1/1D).
01/06/2025
EFFECTS OF ABATACEPT VERSUS HYDROXYCHLOROQUINE ON THE PROGRESSION TO RHEUMATOID ARTHRITIS IN PALINDROMIC RHEUMATISM: ATWO-YEAR MULTICENTER RANDOMIZED CLINICAL TRIAL. THE PALABA STUDY
Sanmarti, R, Perez-Garcia, C, de-Toro-Santos, FJ, Alarcon, GS, Escudero-Contreras, A, Cuervo, A, Graell, E, Reina, D, Binstock, EK, Corominas, H, Urionaguena-Onaindia, I, Lasanta, MAL, Alejandro, O, Gomez, MS, Frade-Sosa, B, Novell, RM, Polino, L, Ostiz, JAM, Oreiro, N, Blanco, FJ, Nadales, IP, Ortega-Castro, R, Busquets-Pérez, N, Gómez-Centeno, A, Camacho, O, Cros, JRR, Arciniegas, AMM, Llorente, JFG, Paños, HB, Prior-Español, A, Quiñones, SC, Cruceta, A, Bonfill, E, Gómez, GD, Fàbregas, AR, Maestre, LT, Gomara, MJ, Haro, I. EFFECTS OF ABATACEPT VERSUS HYDROXYCHLOROQUINE ON THE PROGRESSION TO RHEUMATOID ARTHRITIS IN PALINDROMIC RHEUMATISM: ATWO-YEAR MULTICENTER RANDOMIZED CLINICAL TRIAL. THE PALABA STUDY. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B938. PMID:. IF:20.600(Q1/1D).
01/06/2025
CLINICAL PRESENTATION OF IGG4-RELATED DISEASE. MULTICENTER STUDY AND LITERATURE REVIEW
López-Gutiérrez, F, Loricera, J, Calabuig, PM, Gil, JJF, González-Mazario, R, Hormigos, C, Freites, D, Laguna, MR, Moya, P, Gómez, ML, Corominas, H, Silva-Díaz, M, Arribas, GG, García-Aparicio, A, Font, J, Casafont-Solé, I, Castaneda, E, Argumánez, CM, Zas, R, Molina-Collada, J, Montero, SR, Melero-González, RB, Galindez-Agirregoikoa, E, Hernández, A, Pantoja, L, Abascal, IB, Jovani, V, Valls-Pascual, E, Mena-Vázquez, N, Gallego, A, Cabaleiro-Raña, N, González, RV, Andrés, M, Castañeda, S. CLINICAL PRESENTATION OF IGG4-RELATED DISEASE. MULTICENTER STUDY AND LITERATURE REVIEW. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B3669. PMID:. IF:20.600(Q1/1D).
01/06/2025
ACR/EULAR 2022 CLASSIFICATION CRITERIA COMPARED TO THE ACR 1990 CLASSIFICATION CRITERIA IN THE ARTESER REGISTRY OF GIANT CELL ARTERITIS
De Miguel, E, Dominguez-Alvaro, M, Hernández-Rodríguez, I, Silva-Díaz, M, Otano, JMB, Moya, P, Cabañas, MT, Angeles, VAN, Calvet, J, Casafont-Solé, I, Ivorra, JAR, Labrada-Arrabal, S, Vasques-Rocha, M, Iñiguez, CL, Dorta, AG, Fernández, CC, Villar, MA, Mas, AJ, Prado, FJ, Blanco, R. ACR/EULAR 2022 CLASSIFICATION CRITERIA COMPARED TO THE ACR 1990 CLASSIFICATION CRITERIA IN THE ARTESER REGISTRY OF GIANT CELL ARTERITIS. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B849. PMID:. IF:20.600(Q1/1D).
01/06/2025
VEXAS syndrome through a rheumatologist's lens: insights from a Spanish national cohort
García-Escudero, P, López-Gómez, M, López, BM, Dorta, AG, Frade-Sosa, B, Lizarzaburu, MS, Rúa-Figueroa, I, Fiallo, DV, de Miera, FJTS, Melero-Gonzalez, RB, Santos, DD, Miranda, JA, Belando, CG, Boselli, G, Boteanu, AL, Villalobos, L, Selaya, CC, Santos, CS, Alvarez, ED, Font, J, Alonso, ER, Araguás, ET, Merayo, EE, Rodriguez-Laguna, M, Monjo, I, Gómez, IV, Vela-Casasempere, P, Merino, C, Martínez, MI, Beriain, JAH, Ruiz-Román, A, Calvo-Alén, J. VEXAS syndrome through a rheumatologist's lens: insights from a Spanish national cohort. RHEUMATOLOGY. 2025; 64(6)DOI:10.1093/rheumatology/keaf094. PMID:39937690. IF:4.400(Q1/1D).
01/06/2025
INITIAL THERAPY IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION IMPROVES OUTCOMES ACROSS HAEMODYNAMIC THRESHOLDS AND RISK STRATIFICATION: INSIGHTS FROM THE EUSTAR DATABASE
Bjorkekjar, HJ, Bruni, C, Broch, K, Brunborg, C, Delgado, PC, Airo, P, Simeon-Aznar, CP, Truchetet, ME, Giollo, A, Balbir-Gurman, A, Martin, M, Denton, C, Gabrielli, A, Del Galdo, F, Vonk, M, Fretheim, H, Bitter, H, Midtvedt, O, Andreassen, A, Hoie, S, Tanaka, Y, Riemekasten, G, Mueller-Ladner, U, Matucci-Cerinic, M, Castellvi, I, Siegert, E, Hachulla, E, Molberg, O, Distler, O, Hoffmann-Vold, AM. INITIAL THERAPY IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION IMPROVES OUTCOMES ACROSS HAEMODYNAMIC THRESHOLDS AND RISK STRATIFICATION: INSIGHTS FROM THE EUSTAR DATABASE. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B1890. PMID:. IF:20.600(Q1/1D).
01/06/2025
TRANSITION IN BONE METABOLISM: INSIGHTS FROM A NATIONAL SURVEY IN SPAIN
Lopez, BPM, Lopez-Corbeto, M, Zavala, RG, Torrent, RB, Gonzalez-Fernandez, MI, Perello, CM, Sevilla-Perez, B, Fontana, NP, Pascual, AR, Ildefonso, MMS, Regueira, SM, Alcaniz, P, Gonzalez, JCN, Grana, J. TRANSITION IN BONE METABOLISM: INSIGHTS FROM A NATIONAL SURVEY IN SPAIN. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B1745. PMID:. IF:20.600(Q1/1D).
01/06/2025
COMPARISON OF BARICITINIB AND TOFACITINIB EFFECTIVENESS IN RHEUMATOID ARTHRITIS: INSIGHTS FROM A REAL-WORLD COHORT USING PROPENSITY SCORE ADJUSTMENTS
Lasanta, MAL, Saborit, MC, Panos, HB, Lizarzaburu, MS, Ruiz-Esquide, V, Vilaseca, DR, Nack, A, Perez-Garcia, C, Bernarde, J, Guillen, AG, Aguilar, JR, Cuervo, A, Valls, M, Gomez, CG, Minguez, S, Novell, RM, Alarcon, PE, Martinez-Morillo, M, Grau, CP, Busquets-Perez, N, Park, HS, Gomez-Puerta, JA, Perez, SH, Palau, NM, Sanmarti, R, Mateo-Soria, L, Diaz-Torne, C, Coromina, H, Alarcon, GS. COMPARISON OF BARICITINIB AND TOFACITINIB EFFECTIVENESS IN RHEUMATOID ARTHRITIS: INSIGHTS FROM A REAL-WORLD COHORT USING PROPENSITY SCORE ADJUSTMENTS. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B2477. PMID:. IF:20.600(Q1/1D).
01/06/2025
AMBISPECTIVE, MULTICENTER REGISTRY OF TREATMENT WITH ANIFROLUMAB IN REAL LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM SPANISH RHEUMATOLOGY DEPARTMENTS (ANIFRO-REU): EFFICACY AND SAFETY AT 3-AND 6-MONTH FOLLOW-UP VISITS
Salman-Monte, TC, Carrion-Barberá, I, Triginer, L, Riveros-Frutos, A, Font, J, Garcia-Villanueva, MJ, Garrote-Corral, S, Galindo, M, Polo, CD, González, IA, Bernabéu, P, Casasempere, PV, Morales, CM, Alvarez, ED, Cortés-Hernández, J, Moreno, SS, Giráldez, CR, Gil, JJF, Hernández, A, Magallares, BP, Garcia, MMP, Cid, CMF, Hernández, S, Ros, I, García-Aparicio, A, Sala-Icardo, L, Gómez-Puerta, JA, Frade-Sosa, B, Garcia-Cirera, S, Bufort, MG, Martínez-Barrio, J, de Salazar, JRG, del Amo, ND, Fito-Manteca, C, Torrente-Segarra, V, Heredia, S, Brandy-Garcia, A, Lucea, ER, Zarrabeitia, LR, Urruticoechea-Arana, A, Pego-Reigosa, JM, Rúa-Figueroa, IJ. AMBISPECTIVE, MULTICENTER REGISTRY OF TREATMENT WITH ANIFROLUMAB IN REAL LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM SPANISH RHEUMATOLOGY DEPARTMENTS (ANIFRO-REU): EFFICACY AND SAFETY AT 3-AND 6-MONTH FOLLOW-UP VISITS. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B1338. PMID:. IF:20.600(Q1/1D).
01/06/2025
A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysis
Bjorkekjaer, HJ, Bruni, C, Broch, K, Brunborg, C, Carreira, PE, Airò, P, Simeón-Aznar, CP, Truchetet, ME, Giollo, A, Balbir-Gurman, A, Martin, M, Denton, CP, Gabrielli, A, Del Galdo, F, Vonk, MC, Fretheim, H, Bitter, H, Midtvedt,O, Andreassen, A, Hoie, S, Tanaka, Y, Riemekasten, G, Mueller-Ladner, U, Matucci-Cerinic, M, Castellví, I, Siegert, E, Hachulla, E, Molberg,O, Distler, O, Hoffmann-Vold, AM, EUSTAR Collaborators. A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysis. RHEUMATOLOGY. 2025; 64(6)DOI:10.1093/rheumatology/keaf053. PMID:39878955. IF:4.400(Q1/1D).
22/04/2025
Platelet-Derived Soluble CD40L and Its Impact on Immune Modulation and Anti-IL6R Antibody Treatment Outcome in Rheumatoid Arthritis
Zamora, C, Diaz-Torne, C, Ortiz, MA, Moya, P, Park, HS, Pitarch, C, Cantó, E, Osuna-Gomez, R, Mulet, M, Garcia-Arguinzonis, M, Collado, D, Corominas, H, Vidal, S. Platelet-Derived Soluble CD40L and Its Impact on Immune Modulation and Anti-IL6R Antibody Treatment Outcome in Rheumatoid Arthritis. Cells. 2025; 14(9)DOI:10.3390/cells14090625. PMID:40358149. IF:5.200(Q2/3D).
28/03/2025
Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment
Martinez-Molina, C, Vidal, S, Diaz-Torne, C, Park, HS, Corominas, H. Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment. Frontiers in Medicine. 2025; 12DOI:10.3389/fmed.2025.1512501. PMID:40224626. IF:3.000(Q1/2D).
01/03/2025
Clinical and ultrasound optimization in rheumatoid arthritis for patients in sustained remission, can it work as a new optimization tool?
Añez, G, Torrente-Segarra, V, Bonet, M, Vilella, MC, Orpinell, L, Fernández, AP, Busquets-Pérez, N, Pascual-Pastor, M, Corominas, H, Diaz-Torne, C, Moya, P, De Agustin, JJ. Clinical and ultrasound optimization in rheumatoid arthritis for patients in sustained remission, can it work as a new optimization tool?. Journal Of Ultrasound. 2025; 28(1)DOI:10.1007/s40477-024-00963-z. PMID:39424691. IF:(Q/D).
01/01/2025
EULAR recommendations for the treatment of systemic sclerosis: 2023 update
Del Galdo, F, Lescoat, A, Conaghan, PG, Bertoldo, E, Colic, J, Santiago, T, Suliman, YA, Matucci-Cerinic, M, Gabrielli, A, Distler, O, Hoffmann-Vold, AM, Castellví, I, Balbir-Gurman, A, Vonk, M, Ananyeva, L, Rednic, S, Tarasova, A, Ostojic, P, Boyadzhieva, V, El Aoufy, K, Farrington, S, Galetti, I, Denton, CP, Kowal-Bielecka, O, Mueller-Ladner, U, Allanore, Y. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84(1)DOI:10.1136/ard-2024-226430. PMID:39874231. IF:20.600(Q1/1D).
01/01/2025
Mepolizumab efficacy and safety in patients with eosinophilic granulomatosis with polyangiitis in real practice: Data from a Spanish retrospective multicentric register from Rheumatology departments
Juárez, FR, de Vicuña, RG, Vicente, E, Almaraz, ER, Rivas, NL, González, MF, Marqués, AO, Nack, A, García, JN, Alvarado, PM, Itzazelaia, EU, Lorenzo, NA, de la Fuente, JLM, Ramos, C, Aransay, VP, Alonso, RB, Villanueva, FB, Vidal, MPM, Martín, JMG, Rúa-Figueroa, I. Mepolizumab efficacy and safety in patients with eosinophilic granulomatosis with polyangiitis in real practice: Data from a Spanish retrospective multicentric register from Rheumatology departments. Reumatologia Clinica. 2025; 21(1)DOI:10.1016/j.reuma.2024.10.007. PMID:. IF:(Q/D).
01/11/2024
Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis
Martín-Gutiérrez, A, Loricera, J, Narváez, J, Aldasoro, V, Maiz, O, Vela, P, Romero-Yuste, S, de Miguel, E, Galíndez-Agirregoikoa, E, Fernández-López, JC, Ferraz-Amaro, I, Sánchez-Martín, J, Moya, P, Campos, C, Lopez-Gutierrez, F, Castaneda, S, Blanco, R. Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis. European Journal of Internal Medicine. 2024; 129DOI:10.1016/j.ejim.2024.06.013. PMID:38908981. IF:6.100(Q1/1D).
01/11/2024
Comparative Analysis of Classification Criteria in IgG4-Related Disease and Evaluating Diagnostic Accuracy from a Retrospective Cohort in Clinical Practice
Lopez-Gomez, M, Moya-Alvarado, P, Park, HS, Martín, MC, Calleja, S, Codes-Mendez, H, Magallares, B, Castellví, I, Barros-Membrilla, AJ, Laiz, A, Diaz-Torné, C, Sainz, L, Bernárdez, J, Martínez-Martinez, L, Corominas, H. Comparative Analysis of Classification Criteria in IgG4-Related Disease and Evaluating Diagnostic Accuracy from a Retrospective Cohort in Clinical Practice. Diagnostics. 2024; 14(22)DOI:10.3390/diagnostics14222583. PMID:39594249. IF:3.300(Q1/2D).
18/10/2024
Familial aortic aneurysm: a case presentation
Codes-Méndez, H, Moya-Alvarado, P, Corominas, H. Familial aortic aneurysm: a case presentation. MEDICINA CLINICA. 2024; 163(7)DOI:. PMID:38926034. IF:2.100(Q2/3D).
01/10/2024
Clinical and Serological Profiles in Cryoglobulinemia: Analysis of Isotypes and Etiologies
Codes-Méndez, H, Jeria, S, Park, HS, Moya, P, Magallares-López, B, Moltó, E, Alvaro, Y, Mariscal, A, Moga, E, Tandaipan, JL, Díaz-Torne, C, Laiz, A, Sainz, L, Castellví, I, Corominas, H. Clinical and Serological Profiles in Cryoglobulinemia: Analysis of Isotypes and Etiologies. Journal of Clinical Medicine. 2024; 13(20)DOI:10.3390/jcm13206069. PMID:39458019. IF:2.900(Q1/2D).
01/10/2024
18F-FDG-PET/CT Scan for Detection of Large Vessel Involvement in Giant Cell Arteritis: Arteser Spanish Registry
Estrada, P, Domínguez-Alvaro, M, Melero-González, RB, de Miguel, E, Silva-Díaz, M, Valero, JA, González, I, Sánchez-Martín, J, Narváez, J, Galíndez, E, Mendizábal, J, Iñiguez-Ubiaga, CL, Rodríguez-Rodríguez, L, Loricera, J, Muñoz, A, Moya-Alvarado, P, Moran-alvarez, P, Navarro-angeles, VA, Galisteo, C, Castañeda, S, Blanco, R. 18F-FDG-PET/CT Scan for Detection of Large Vessel Involvement in Giant Cell Arteritis: Arteser Spanish Registry. Journal of Clinical Medicine. 2024; 13(20)DOI:10.3390/jcm13206215. PMID:39458165. IF:2.900(Q1/2D).
01/10/2024
Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological and synthetic targeted therapies in rheumatoid arthritis.
Álvaro-Gracia Álvaro JM, Díaz Del Campo Fontecha P, Andréu Sánchez JL, Balsa Criado A, Cáliz Cáliz R, Castrejón Fernández I, Corominas H, Gómez Puerta JA, Manrique Arija S, Mena Vázquez N, Ortiz García A, Plasencia Rodríguez C, Silva Fernández L, Tornero Molina J. Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological and synthetic targeted therapies in rheumatoid arthritis.. Reumatologia Clinica. 2024; 20(8)DOI:10.1016/j.reumae.2024.09.002. PMID:39341701. IF:(Q/D).
01/09/2024
Ultrasound in Rheumatology, It is a Must
Corominas, H, Badlissi, F. Ultrasound in Rheumatology, It is a Must. European Journal Of Rheumatology. 2024; 11DOI:10.5152/eurjrheum.2024.250324. PMID:39308354. IF:(Q/D).
01/09/2024
Ultrasound for the Diagnosis of Giant Cell Arteritis
Alarcón, PVE, Alvarado, PM, Alierta, ELS. Ultrasound for the Diagnosis of Giant Cell Arteritis. European Journal Of Rheumatology. 2024; 11DOI:10.5152/eurjrheum.2024.20104. PMID:39311386. IF:(Q/D).
01/09/2024
SSc-PAH patients are at risk of disease progression in contemporary clinical practice
Bjorkekjær, HJ, Bruni, C, Brunborg, C, Carreira, P, Airò, P, Simeón-Aznar, CP, Truchetet, ME, Giollo, A, Balbir-Gurman, A, Martin, M, Denton, CP, Gabrielli, A, Fretheim, H, Bitter, H, Midtvedt, O, Broch, K, Andreassen, A, Hoie, S, Tanaka, Y, Riemekasten, G, Müller-Ladner, U, Matucci-Cerinic, M, Castellví, I, Siegert, E, Hachulla, E, Molberg, O, Distler, O, Hoffmann-Vold, AM. SSc-PAH patients are at risk of disease progression in contemporary clinical practice. EUROPEAN RESPIRATORY JOURNAL. 2024; 64DOI:10.1183/13993003.congress-2024.PA2493. PMID:. IF:21.000(Q1/1D).
01/09/2024
ACR/EULAR 2022 Classification Criteria Compared to the ACR 1990 Classification Criteria in the ARTESER Registry of Giant Cell Arteritis
De Miguel, E, Hern ndez-Rodr guez, I, Silva-Diaz, M, Belzunegui, JM, Moya, P, Tortosa-Caba as, M, Navarro, VA, Calvet, J, Casafont-Sol , I, Rom n-Ivorra, JA, Labrada-Arrabal, S, Rocha, MV, I iguez, CL, Hern ndez-Hern ndez, V, Campos-Fern ndez, C, Villar, MA, Juan-Mas, A, Prado-Galbarro, FJ, Calvo, I, S nchez-Mart n, J, Narvaez-Garc a, J, Blanco-Alonso, R. ACR/EULAR 2022 Classification Criteria Compared to the ACR 1990 Classification Criteria in the ARTESER Registry of Giant Cell Arteritis. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024
Clinical Patterns and Long-term Outcomes of Arthritis Triggered by Immune Checkpoint Inhibitors. A Multicenter Study
Narvaez-Garc a, J, Llobell, A, Ponce, A, Gomez-Centeno, A, Mill n, AM, Corominas, H, Nolla, JM, Gomez-Puerta, JA. Clinical Patterns and Long-term Outcomes of Arthritis Triggered by Immune Checkpoint Inhibitors. A Multicenter Study. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024
Ambispective, Multicenter Registry of Treatment with Anifrolumab in Real Life in Patients with Systemic Lupus Erythematosus from Spanish Rheumatology Departments (ANIFRO-Reu): Efficacy, Safety and Patient's Characteristics
Carri n-Barber , I, Monte, TCS, Triginer, L, Garc a-Villanueva, M, Corral, SG, Frutos, AR, Font, J, Galindo-Izquierdo, M, Polo, CDF, Gil, JJF, Moriano, C, Alvarez, ED, Bernab u, P, Vela-Casasempere, P, Cortes-Hern ndez, J, Moreno, SS, Narvaez-Garc a, J, Hern ndez-Mart n, A, Magallares, BP, Garc a, MP, Marras, C, Ramos, C, Gomez-Puerta, JA, Frade-Sosa, B, Fern ndez-Ortiz, A, Garcia-Aparicio, A, Altab s-Gonz lez, I, Hern ndez-Baldiz n, S, Ros-Vilamajo, I, Cirera, SG, Bufort, MG, Sala, L, Mart nez-Barrio, J, de Salazar, JRG, Heredia, S, Torrente-Segarra, V, Brandy-Garcia, AM, Del Amo, NDV, Fito-Manteca, C, Calvo-Alen, J, Pego-Reigosa, JM, R a-Figueroa, I. Ambispective, Multicenter Registry of Treatment with Anifrolumab in Real Life in Patients with Systemic Lupus Erythematosus from Spanish Rheumatology Departments (ANIFRO-Reu): Efficacy, Safety and Patient's Characteristics. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024
Sustained Drug-free Remission in Giant Cell Arteritis: Results Results of the Spanish ARTESER Registry
Narvaez-Garc a, J, Dominguez-Alvaro, M, Gal ndez-Agirregoikoa, E, Mendizabal, J, Alcazar, IA, Loricera, J, Garrido-Pu al, N, Casta eda, S, Moya, P, Larena, C, Estrada-Alarc n, P, Galisteo, C, Frutos, AR, Sanjuan, FO, Monte, TCS, Rocha, MV, Ubiaga, CLI, Garcia-Gonzalez, M, Blanco-Alonso, R. Sustained Drug-free Remission in Giant Cell Arteritis: Results Results of the Spanish ARTESER Registry. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024
Sex Differences in Phenotypes and Imaging Examination in Giant Cell Arteritis: Data from the ARTESER Registry
Fern ndez-Lozano, D, Dom nguez-Alvaro, M, Narvaez-Garc a, J, Garrido-Pu al, N, De Miguel, E, Estrada-Alarc n, P, Hern ndez-Rodr guez, I, Silva-Diaz, M, Belzunegui, JM, Moriano, C, S nchez-Mart n, J, Calvo, I, Aldasoro, V, Alcazar, LA, Loricera, J, Moya, P, Garc a-Villanueva, M, S nchez-Alonso, F, Casta eda, S, Hern ndez, JL, Blanco-Alonso, R. Sex Differences in Phenotypes and Imaging Examination in Giant Cell Arteritis: Data from the ARTESER Registry. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024
Therapeutic Insights in VEXAS Syndrome from a Multicenter Study in Spain: Moving Towards Amore Specific and Effective Treatment
G mez, MLI, Escudero, PG, L pez, BM, Dorta, AG, Frade-Sosa, B, Lizarzaburu, MS, R a-Figueroa, I, Su rez, DVF, de Miera, FJTS, Melero-Gonzalez, RB, Santos, DD, Miranda, JA, Belando, CG, Boselli, G, Boteanu, AL, Selaya, CC, Santos, CS, Alvarez, ED, Font, J, Alonso, ER, Aragu s, ET, Merayo, EE, Rodriguez-Laguna, M, Monjo, I, G mez, IV, Vela-Casasempere, P, Merino, C, Mart nez, MI, Beriain, JAH, Roman, AMR, Calvo-Al n, J. Therapeutic Insights in VEXAS Syndrome from a Multicenter Study in Spain: Moving Towards Amore Specific and Effective Treatment. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024
Safety and Efficacy of Subcutaneous Ianalumab (VAY736) for up to 68 Weeks in Patients with Systemic Lupus Erythematosus: Results from Phase 2 Study
Mysler, E, Ignatenko, S, Gordienko, A, Cort s-Hern ndez, J, Agmon-Levin, N, Narongroeknawin, P, Romanowska-Prochnicka, K, Shen, N, Cifersk , H, Kodera, M, Wei, JCC, Leszczynski, P, Lan, JL, Wojciechowski, R, Tarr, T, Vishneva, E, Chen, YH, Kaneko, Y, Finzel, S, Hoi, A, Okada, M, Koolvisoot, A, Lee, SS, Dai, L, Kaneko, H, Rojkovich, B, Sun, LY, Zotkin, E, Viallard, JF, Magallares, BP, Sengupta, T, Sips, C, Lau, C, Avrameas, A, Oliver, SJ. Safety and Efficacy of Subcutaneous Ianalumab (VAY736) for up to 68 Weeks in Patients with Systemic Lupus Erythematosus: Results from Phase 2 Study. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024
Delphi Survey to Establish Consensus on the OMERACT Core Domain Set for Long-Term Studies of Calcium Pyrophosphate Deposition Disease
Zhang, YL, Tedeschi, S, Abhishek, A, Hensey, O, Grossberg, D, Cai, K, Shea, B, Singh, J, Christensen, R, Serban, T, Cipolletta, E, Parperis, K, D az, C, McCarthy, G, Becce, F, Gheita, TA, Sirotti, S, Christiansen, SN, Tarancon, LC, Stamp, L, Abdel-Fattah, YH, Pascart, T, Filippou, G, Hong, LE, FitzGerald, J, Dalbeth, N. Delphi Survey to Establish Consensus on the OMERACT Core Domain Set for Long-Term Studies of Calcium Pyrophosphate Deposition Disease. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024
Effectiveness of Rituximab in IgG4 Related Disease
Lopez-Gutierrez, F, Loricera, J, Hormigos, C, Nu ez, DF, Rodriguez-Laguna, M, Albarado, PM, G mez, MLI, Corominas, H, Silva-D az, M, Arribas, GG, Garcia-Aparicio, A, Urgelles, JF, Casafont-Sole, I, Calabuig, PM, Castaneda, E, Merino, C, Zas, R, Molina-Collada, J, Melero-Gonzalez, RB, Galindez-Agirregoikoa, E, Hern ndez-Mart n, A, Pantoja, L, Abascal, IB, Jovani, V, Valls-Pascual, E, V zquez, NM, Gallego-Flores, A, Ra a, NC, Veroz, R, Andres, M, Casta eda, S, Blanco-Alonso, R. Effectiveness of Rituximab in IgG4 Related Disease. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024
Evaluation of the New Criteria for Progressive Pulmonary Fibrosis in Patients with Systemic Sclerosis
Guerrero, MR, Moriano, C, Santos, CS, Herranz, LS, Garcia, JJ, Barranco, IC, Alvarez, ED. Evaluation of the New Criteria for Progressive Pulmonary Fibrosis in Patients with Systemic Sclerosis. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024
Mapping Monosodium Urate Crystal Deposition Within Joints in Tophaceous Gout: A Dual Energy CT Study
De Silva, C, D az, C, Gamble, G, Horne, A, Doyle, A, Stamp, L, Dalbeth, N. Mapping Monosodium Urate Crystal Deposition Within Joints in Tophaceous Gout: A Dual Energy CT Study. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024
Evaluation of the Survival and Safety of Biologic and Targeted Synthetic DMARD in Patients with Difficult-to-Treat RA Using Real-World Data from a Nationwide Registry of Rheumatic Diseases
Quevedo-Rodr guez, A, Otero-Varela, L, S nchez-Alonso, F, P rez-Vera, Y, Manero-Ruiz, J, Campos-Fern ndez, C, Manrique-Arija, S, Vela-Casasempere, P, Mera-Varela, A, D az, C, Movasat, A, Garcia-Magallon, B, Ros-Vilamaj , I, Perez-Garcia, C, Castrejon, I. Evaluation of the Survival and Safety of Biologic and Targeted Synthetic DMARD in Patients with Difficult-to-Treat RA Using Real-World Data from a Nationwide Registry of Rheumatic Diseases. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024
Features of Anti-Fibrillarin Positive Systemic Sclerosis Patients and Ethnic Differences: A European Multicenter Cohort
D'Alessandro, R, Rodolfi, S, Calot, A, Bebear, L, Campochiaro, C, Codullo, V, Del Galdo, F, Barranco, IC, Zanatta, E, Randone, SB, Boleto, G, Raffray, L, Chatelus, E, Cacoub, P, Le Joncour, A, Airo, P, Santos, CS, Lescoat, A, Avouac, J, Denton, C, Allanore, Y. Features of Anti-Fibrillarin Positive Systemic Sclerosis Patients and Ethnic Differences: A European Multicenter Cohort. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024
Prognostic Value of Hyperuricemia in Developing Cardiovascular Events in Patients with Chronic Inflammatory Arthritis: A 10-Year Prospective Study
Avil s, A, Plaza, Z, S nchez-Alonso, F, Casta eda, S, Fernandez-Gutierrez, B, D az, C, Font, P, Martinez, O, Giner, E, Senabre, JM, Rueda, A, Perez, A, Sanchez, G, Gonzalez, C, Garc a, J, Llorca, J, Gonzalez-Gay, MA, Andres, M. Prognostic Value of Hyperuricemia in Developing Cardiovascular Events in Patients with Chronic Inflammatory Arthritis: A 10-Year Prospective Study. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024
Phenotypical Differences in VEXAS Syndrome, Where Are We a Year Later? Results from a National Cohort Focused on Rheumatological Patients
Escudero, PG, G mez, MLI, L pez, BM, Santos, DD, de Miera, FJTS, Dorta, AG, Beriain, JAH, R a-Figueroa, I, Santos, CS, Alvarez, ED, Mart nez, MI, Frade-Sosa, B, Urgelles, JF, Lizarzaburu, MS, Alonso, ER, Aragu s, ET, Merayo, EE, Rodriguez-Laguna, M, Monjo, I, Merino, C, Vela-Casasempere, P, G mez, IV, Filloy, JAM, Melero-Gonzalez, RB, Belando, CG, Boselli, G, Boteanu, AL, Su rez, DVF, Selaya, CC, Roman, AMR, Calvo-Al n, J. Phenotypical Differences in VEXAS Syndrome, Where Are We a Year Later? Results from a National Cohort Focused on Rheumatological Patients. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024
[Translated article] Improvements in the Management of Patients With Generalized Pustular Psoriasis in Spain: Recommendations From a Group of Experts.
Rivera-Díaz R, Carrascosa Carrillo JM, Alfonso Zamora S, Navarro Valdivieso JP, Muñoz Cabello B, Ros Abarca S, Soria de Francisco JM, Daudén Tello E. [Translated article] Improvements in the Management of Patients With Generalized Pustular Psoriasis in Spain: Recommendations From a Group of Experts.. Actas Dermo-Sifiliograficas. 2024; 115(8)DOI:10.1016/j.ad.2024.07.012. PMID:38972580. IF:(Q/D).
01/05/2024
Cardiovascular disease in patients with systemic autoimmune diseases: The relationship between self-perceived risk and actual risk
Santos, CS, Oliveira, MM, Solari, PN, Mateus, P, Santos, MJ, Corominas, H, Castro, CA, Alvarez, ED. Cardiovascular disease in patients with systemic autoimmune diseases: The relationship between self-perceived risk and actual risk. Reumatologia Clinica. 2024; 20(5)DOI:10.1016/j.reuma.2024.01.002. PMID:38880551. IF:(Q/D).
01/04/2024
3D-DXA based finite element modelling for femur strength prediction: evaluation against QCT.
Qasim, M, Picazo, ML, Wills, CR, Noailly, J, Di Gregorio, S, Barquero, LMD, Sierra, JM, Humbert, L. 3D-DXA based finite element modelling for femur strength prediction: evaluation against QCT.. JOURNAL OF CLINICAL DENSITOMETRY. 2024; 27(2)DOI:10.1016/j.jocd.2024.101471. PMID:38306806. IF:1.600(Q4/9D).
01/04/2024
SER recommendations on treatment of refractory Behc , et's syndrome
Morales, CM, Gil, JG, García, NB, Varillas, JLM, del Río, VC, Alvarado, PM, García, FJN, Espinosa, G, Fontecha, PDD, Rodríguez, MG, Arranz, JM, Gómez, ML, Hernández, FMF, Trujillo, MM, Sobrín, RD, Sánchez, JIM, Manzano, JM, Cuba, JS. SER recommendations on treatment of refractory Behc , et's syndrome. Reumatologia Clinica. 2024; 20(4)DOI:10.1016/j.reuma.2023.12.001. PMID:38614885. IF:(Q/D).
01/03/2024
Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register
Fernández-Lozano, D, Hernández-Rodríguez, I, Narvaez, J, Domínguez-Alvaro, M, De Miguel, E, Silva-Díaz, M, Belzunegui, JM, Morales, CM, Sánchez, J, Galíndez-Agirregoikoa, E, Aldaroso, V, Abasolo, L, Loricera, J, Garrido-Puñal, N, Alvarado, PM, Larena, C, Navarro, VA, Calvet, J, Casafont-Solé, I, Ortiz-Sanjuán, F, Monte, TCS, Castañeda, S, Blanco, R. Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register. RMD Open. 2024; 10(1)DOI:10.1136/rmdopen-2023-003824. PMID:38531620. IF:4.700(Q1/1D).
01/03/2024
Persistentsciatic artery, an uncommon cause of femoropopliteal occlusion
Casademont, EB, Molina, JM. Persistentsciatic artery, an uncommon cause of femoropopliteal occlusion. Angiologia. 2024; 76(2)DOI:10.20960/angiologia.00496. PMID:. IF:(Q/D).
26/02/2024
Prognostic significance of lymphocytic foci composition in minor salivary gland biopsies for severe disease flare and severity in Sjögren's syndrome: a 3-year follow-up cohort study
Park, HS, Martínez-Martínez, L, López, BM, Castellví, I, Moya, P, Codes-Mendez, H, Sosa, NH, Diaz-Torne, C, Laiz, A, Sainz, L, Tandaipan, JL, Mariscal, A, Franco-Leyva, T, Casademont, J, Juarez, C, Corominas, H. Prognostic significance of lymphocytic foci composition in minor salivary gland biopsies for severe disease flare and severity in Sjögren's syndrome: a 3-year follow-up cohort study. Frontiers in Immunology. 2024; 15DOI:10.3389/fimmu.2024.1332924. PMID:38469314. IF:5.900(Q1/2D).
01/02/2024
Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register
Molina-Collada, J, Alonso, F, Otero, L, Bohórquez, C, Torné, CD, García, CP, Madrigal, JMB, Vela, P, Alvaro-Gracia, JM, Castrejón, I. Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register. SEMINARS IN ARTHRITIS AND RHEUMATISM. 2024; 64DOI:10.1016/j.semarthrit.2023.152341. PMID:38128174. IF:4.400(Q1/1D).
01/02/2024
Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study
López-Medina, C, Calvo-Gutiérrez, J, Abalos-Aguilera, MC, Cepas, F, Plasencia-Rodríguez, C, Martínez-Feito, A, Balsa, A, Faré-García, R, Juan-Mas, A, Ruiz-Esquide, V, Sainz, L, Díaz-Torné, C, Godoy-Navarrete, FJ, Añón-Oñate, I, Mena-Vázquez, N, Manrique-Arija, S, Moreno-García, MS, Ortega-Castro, R, Escudero-Contreras, A. Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study. RMD Open. 2024; 10(1)DOI:10.1136/rmdopen-2023-003975. PMID:38395455. IF:4.700(Q1/1D).